{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:51:27Z","timestamp":1747158687737,"version":"3.40.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:00:00Z","timestamp":1729382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ctro.2024.100879","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T10:09:47Z","timestamp":1730196587000},"page":"100879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-5439","authenticated-orcid":false,"given":"Daniel","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9354-4223","authenticated-orcid":false,"given":"Connor","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas M.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0497-9637","authenticated-orcid":false,"given":"Randy F.","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9083-1435","authenticated-orcid":false,"given":"Paul J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-2527","authenticated-orcid":false,"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell Z.","family":"Szmulewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott E.","family":"Eggener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arieh L.","family":"Shalhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley L.","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Pitroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100879_b0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctro.2024.100879_b0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.clgc.2019.10.006","article-title":"Percutaneous ablation versus robotic partial nephrectomy in the treatment of cT1b renal tumors: oncologic and functional outcomes of a propensity score-weighted analysis","volume":"18","author":"Rembeyo","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctro.2024.100879_b0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/02656736.2018.1475684","article-title":"Local tumor progression after ultrasound-guided percutaneous microwave ablation of stage T1a renal cell carcinoma: risk factors analysis of 171 tumors","volume":"35","author":"Hao","year":"2018","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ctro.2024.100879_b0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/bju.12349","article-title":"Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours","volume":"113","author":"Wah","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.ctro.2024.100879_b0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0360-3016(95)02029-2","article-title":"A review of human cell radiosensitivity in vitro","volume":"34","author":"Deschavanne","year":"1996","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0030","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0035","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for \u2265T1b primary renal cell carcinoma: a report from the international radiosurgery oncology consortium for kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0040","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/JU.0000000000000111","article-title":"Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: a multicenter analysis from the IROCK","volume":"201","author":"Correa","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2024.100879_b0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2023.02.016","article-title":"Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer","volume":"84","author":"Hannan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2024.100879_b0055","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon Alfa-2b compared with interferon Alfa-2b alone for metastatic renal-cell cancer","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2024.100879_b0060","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2024.100879_b0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2024.100879_b0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol"},{"unstructured":"R Core Team (2024). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; n.d.","key":"10.1016\/j.ctro.2024.100879_b0075"},{"key":"10.1016\/j.ctro.2024.100879_b0080","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0085","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.eururo.2012.01.001","article-title":"Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up","volume":"61","author":"Olweny","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2024.100879_b0090","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.urology.2010.12.077","article-title":"Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma","volume":"77","author":"Zagoria","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.ctro.2024.100879_b0095","doi-asserted-by":"crossref","first-page":"23721","DOI":"10.1073\/pnas.2001933117","article-title":"Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients","volume":"117","author":"Chow","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ctro.2024.100879_b0100","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-16-2946","article-title":"A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctro.2024.100879_b0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-018-0992-3","article-title":"A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma","volume":"13","author":"Correa","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0110","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/sajc.sajc_7_19","article-title":"Case report on stereotactic body radiation therapy for locally recurrent renal cell carcinoma after partial nephrectomy in a patient with single kidney","volume":"08","author":"Kataki","year":"2019","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.ctro.2024.100879_b0125","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1002\/cam4.4790","article-title":"Locoregional recurrence after nephrectomy for localized renal cell carcinoma: feasibility and outcomes of different treatment modalities","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"doi-asserted-by":"crossref","unstructured":"Maclean J, Breau RH, Scheida N, Malone S. Durable control of locally recurrent renal cell carcinoma using stereotactic body radiotherapy. BMJ Case Rep 2014:bcr2014206015. doi: 10.1136\/bcr-2014-206015.","key":"10.1016\/j.ctro.2024.100879_b0130","DOI":"10.1136\/bcr-2014-206015"},{"key":"10.1016\/j.ctro.2024.100879_b0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1464-410X.2010.09241.x","article-title":"Changes in symptoms of renal cell carcinoma over four decades","volume":"106","author":"Sunela","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ctro.2024.100879_b0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12894-024-01405-y","article-title":"Neoadjuvant stereotactic ablative body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumor thrombus: a prospective pilot study","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.ctro.2024.100879_b0145","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ijrobp.2021.01.054","article-title":"Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus\u2014safety lead-in results of a phase 2 trial","volume":"110","author":"Margulis","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100879_b0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40425-019-0546-8","article-title":"Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy","volume":"7","author":"Labbate","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctro.2024.100879_b0155","first-page":"166.e9","article-title":"Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus","volume":"40","author":"Freifeld","year":"2022","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.ctro.2024.100879_b0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13014-024-02413-w","article-title":"Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer","volume":"19","author":"Ali","year":"2024","journal-title":"Radiat Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824001563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824001563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T13:50:35Z","timestamp":1730555435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824001563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":32,"alternative-id":["S2405630824001563"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100879","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100879"}}